DHR:NYSEDanaher Corporation Analysis
Data as of 2026-05-25 - not real-time
$172.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Danaher’s stock trades around $172, just above its 20‑day SMA (≈$171.8) but comfortably below the 50‑day SMA (≈$182.9), signaling a short‑term bearish bias despite a bullish MACD histogram and a neutral RSI near 45. High 30‑day volatility (~29%) and a bearish trend direction compound the downside risk, while the beta of ~0.75 suggests the stock moves less than the market overall. Fundamentally, the company appears overvalued, with a trailing P/E of 33× versus the industry average of 27× and a DCF fair‑value estimate of roughly $79, far below the current price.
Recent earnings disappointed investors, yet the business continues to generate strong cash flow, a low payout ratio (~26%) and a sustainable dividend yield of 0.9%. Forward EPS is projected to rise to $9.09, cutting the forward P/E to ~19× and supporting a 44% upside target from analysts. The combination of solid fundamentals, a low‑beta defensive profile, and a strong‑buy consensus suggests a medium‑term buying case, while short‑term caution remains warranted due to technical weakness and valuation concerns.
Recent earnings disappointed investors, yet the business continues to generate strong cash flow, a low payout ratio (~26%) and a sustainable dividend yield of 0.9%. Forward EPS is projected to rise to $9.09, cutting the forward P/E to ~19× and supporting a 44% upside target from analysts. The combination of solid fundamentals, a low‑beta defensive profile, and a strong‑buy consensus suggests a medium‑term buying case, while short‑term caution remains warranted due to technical weakness and valuation concerns.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price below 50‑day SMA indicating bearish momentum
- Recent earnings miss dampening short‑term sentiment
- High volatility and proximity to support level
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward EPS growth and reduced forward P/E around 19×
- Strong cash generation and sustainable dividend
- Analyst consensus strong‑buy with ~44% upside potential
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Significant valuation gap between market price and DCF fair value
- Stable business model with low beta and defensive cash flow
- Ongoing regulatory and geopolitical exposure
Key Metrics & Analysis
Financial Health
Revenue Growth3.70%
Profit Margin14.89%
P/E Ratio33.3
ROE7.08%
ROA4.19%
Debt/Equity37.17
P/B Ratio2.3
Op. Cash Flow$6.4B
Free Cash Flow$4.6B
Industry P/E27.6
Technical Analysis
TrendBearish
RSI44.5
Support$160.93
Resistance$183.00
MA 20$171.77
MA 50$182.91
MA 200$206.57
MACDBullish
VolumeStable
Fear & Greed Index91.8
Valuation
Fair Value$78.75
Target Price$247.83
Upside/Downside44.08%
GradeOvervalued
TypeBlend
Dividend Yield0.93%
Risk Assessment
Beta0.75
Volatility28.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.